SCHEMBL19437468

SCHEMBL19437468

CC(C)(C)OC(=O)N(CCOCCOCCOCCN=[N+]=[N-])CCOCCOCCOCCN=[N+]=[N-]

nearest known ligand 0.37

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31618231 1.00 CA14 (0.37) CA14
SCHEMBL24068405 0.95 CA14 (0.36) CA14
SCHEMBL25756359 0.93 CA14 (0.37) CA14
SCHEMBL31191847 0.92 CA14 (0.33) CA14
SCHEMBL23765709 0.92 CA14 (0.35) CA14
SCHEMBL24068409 0.92 CA14 (0.33) CA14
SCHEMBL24068676 0.92 CA14 (0.33) CA14
SCHEMBL25031581 0.92 CA14 (0.35) CA14
SCHEMBL24068328 0.92 CA14 (0.33) CA14
SCHEMBL23766011 0.92 CA14 (0.33) CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083851-A1 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2026-03-26 US disclosed
EP-3736572-B1 INTRA-DROPLET SURFACE ENGINEERING TO CAPTURE A MOLECULAR TARGET UNIV STRASBOURG (FR) 2024-07-24 EP disclosed
WO-2024098039-A2 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-05-10 WO disclosed
US-20220074930-A1 INTRA-DROPLET SURFACE ENGINEERING TO CAPTURE A MOLECULAR TARGET UNIVERSITE DE STRASBOURG (FR) 2022-03-10 US disclosed
US-11181521-B2 Intra-droplet surface engineering to capture a molecular target UNIVERSITE DE STRASBOURG (FR) 2021-11-23 US disclosed
US-11181521-B2 Intra-droplet surface engineering to capture a molecular target UNIVERSITE DE STRASBOURG (FR) 2021-11-23 US disclosed
EP-3736572-A1 INTRA-DROPLET SURFACE ENGINEERING TO CAPTURE A MOLECULAR TARGET Université de Strasbourg (FR) 2020-11-11 EP disclosed
EP-3440463-B1 INTRA-DROPLET SURFACE ENGINEERING TO CAPTURE A MOLECULAR TARGET UNIV STRASBOURG (FR) 2020-07-08 EP disclosed
US-20190113509-A1 INTRA-DROPLET SURFACE ENGINEERING TO CAPTURE A MOLECULAR TARGET CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-04-18 US disclosed
US-20190113509-A1 INTRA-DROPLET SURFACE ENGINEERING TO CAPTURE A MOLECULAR TARGET CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-04-18 US disclosed
EP-3440463-A1 INTRA-DROPLET SURFACE ENGINEERING TO CAPTURE A MOLECULAR TARGET Université de Strasbourg (FR) 2019-02-13 EP disclosed
WO-2017174610-A1 INTRA-DROPLET SURFACE ENGINEERING TO CAPTURE A MOLECULAR TARGET UNIVERSITE DE STRASBOURG (FR) 2017-10-12 WO disclosed
WO-2017174610-A1 INTRA-DROPLET SURFACE ENGINEERING TO CAPTURE A MOLECULAR TARGET UNIVERSITE DE STRASBOURG (FR) 2017-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260083851-A1 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS ASGR1, FCGR2A, FCGR3B CA14 2998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.